REG - Indivior PLC - Director Declaration

IndiviorAnnouncement

15/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241115:nRSO3446Ma&default-theme=true

RNS Number : 3446M  Indivior PLC  15 November 2024

INDIVIOR PLC (the 'Company')

DIRECTOR DECLARATION

Richmond, VA, and Slough, UK, November 15, 2024 - The Board of Directors of
Indivior PLC (https://www.indivior.com/en) (Nasdaq/LSE: INDV) have agreed that
Jerome Lande will continue to serve as a Non-Executive Director until December
31, 2024, whereupon he will step down from the Board.

The Company's relationship agreement with Scopia Capital Management LP
("Scopia"), otherwise due to expire on December 31, 2024, has terminated in
accordance with its terms because the aggregate of Scopia's and its
affiliates' interests in the issued share capital of the Company has reduced
below the threshold for automatic termination. Notwithstanding that the
threshold for automatic termination has been crossed, the Board and Scopia
have agreed that Jerome Lande will continue to serve as a Non-Executive
Director until December 31, 2024.

The Board would like to express its sincere thanks to Jerome for his
significant contribution to Indivior since joining the Board in 2021.

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD), overdose
and serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from
a global human crisis to a recognized and treated chronic disease. Building on
its global portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of
SUD. Headquartered in the United States in Richmond, VA, Indivior employs over
1,000 individuals globally and its portfolio of products is available in over
30 countries worldwide. Visit www.indivior.com
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.indivior.com%2F&data=05%7C02%7Cdavid.wisniewski%40Indivior.com%7C46151793371f4a5a147b08dced4812d0%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C638646141028285945%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=vwwjBavEG8GHlzYIHaEEC6eKfaZlLZYEsM1w5sIS1B8%3D&reserved=0)
to learn more. Connect with Indivior on LinkedIn by visiting
www.linkedin.com/company/indivior
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Findivior&data=05%7C02%7Cdavid.wisniewski%40Indivior.com%7C46151793371f4a5a147b08dced4812d0%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C638646141028306668%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=mWdLO9fvlp1vQv6%2F30I2DGhuwyieW3W262QTgrk4ZVQ%3D&reserved=0)
.

 

For Further Information

                                       VP, Investor Relations                      +1 804 402 7123

 Investor Enquiries   Jason Thompson   Indivior PLC                                jason.thompson@indivior.com
                      Tim Owens                                                    +1 804 263 3978

                                       Director, Investor Relations Indivior PLC   timothy.owens@indivior.com
 Media Enquiries      Jonathan Sibun   Teneo                                       +44 (0)20 7353 4200

                                       U.S. Media Inquiries                        +1 804 594 0836

                                                                                   Indiviormediacontacts@indivior.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RDNQKQBKNBDBFDD